No Data
sh pharma (601607.SH): The application for the market approval of butanedioic acid linagliptin ester capsules has been approved.
On December 4, Gelonghui reported that sh pharma (601607.SH) announced that in October 2021, its wholly-owned subsidiary Shanghai Shennong Xinyi Pharmaceutical Factory Co., Ltd. signed a "Cooperation Agreement" with Guizhou Shengnuo Biotechnology Co., Ltd. and its wholly-owned subsidiary, obtaining exclusive commission manufacturing and industrial sales rights for the active pharmaceutical ingredient and formulation of the X842 project (i.e., "pentanedioic acid linaclotide ester capsules") in the region of china. Recently, the X842 project developed in cooperation with Guizhou Shengnuo has received the "Drug Registration Certificate" issued by the National Medical Products Administration, and the drug market approval application has been approved by the National Medical Products Administration.
Shanghai Pharma Gets Nod to Produce Apremilast Tablets
Market bullish stimulus boosts Hong Kong pharmaceutical stocks, with Genshuo Niaoyao rising over 14%.
① What bullish impacts does the medical insurance centralized procurement have on pharmaceutical companies? ② How do institutions view the subsequent development of pharmaceutical stocks?
Shanghai Pharmaceuticals Holding Co., Ltd (SHSE:601607) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?
Shanghai Pharmaceuticals' Trial on Drug for Stroke Patients Shows Positive Results
China Securities Co.,Ltd.: In the 2024 version of the medical insurance catalog, the number of innovative drugs added has reached a new high, balancing 'ensuring basic coverage' and 'supporting genuine innovation'.
Overall situation of the 2024 medical insurance catalog: the results are stable, meeting expectations, with a record high in the number of new innovative drugs, reflecting a balanced consideration of fund safety, public medical needs, and support for innovation.
Return Trends At Shanghai Pharmaceuticals Holding (SHSE:601607) Aren't Appealing
No Data
